Abstract
Staphylococcus aureus causes many diseases including cellulitis, keratitis, osteomyelitis, septic arthritis and mastitis. The heptapeptide RIP has been shown to prevent cellulitis in mice, which was induced by S. aureus strain Smith diffuse. Here we show that RIP can also significantly reduce the overall pathology and delay the onset of disease symptoms in several other models of S. aureus infections, including: keratitis (tested in rabbits against S. aureus 8325-4), osteomyelitis (tested in rabbits against S. aureus MS), mastitis (tested in cows against S. aureus Newbould 305, AE-1, and environmental infections) and septic arthritis (tested in mice against S. aureus LS-1). These findings substantiate that RIP is not strain specific in its inhibitory activity and that RIP is an effective inhibitor of bacterial pathology at multiple body sites following diverse routes and doses of administration. These findings strongly evidence the potential value of RIP as a chemotherapeutic agent. Copyright (C) 2000 Elsevier Science Inc.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1301-1311 |
| Number of pages | 11 |
| Journal | Peptides |
| Volume | 21 |
| Issue number | 9 |
| DOIs | |
| State | Published - 2000 |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Endocrinology
- Physiology
- Cellular and Molecular Neuroscience
Cite this
Prevention of diseases caused by Staphylococcus aureus using the peptide RIP. / Balaban, Naomi; Collins, L. Vincent; Cullor, James S; Hume, Emma B.; Medina-Acosta, Enrique; Vieira da Motta, Olney; O'Callaghan, Richard; Rossitto, Paul V.; Shirtliff, Mark E.; Serafim da Silveira, Leonardo; Tarkowski, Andrej; Torres, Jose V.
In: Peptides, Vol. 21, No. 9, 2000, p. 1301-1311.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prevention of diseases caused by Staphylococcus aureus using the peptide RIP
AU - Balaban, Naomi
AU - Collins, L. Vincent
AU - Cullor, James S
AU - Hume, Emma B.
AU - Medina-Acosta, Enrique
AU - Vieira da Motta, Olney
AU - O'Callaghan, Richard
AU - Rossitto, Paul V.
AU - Shirtliff, Mark E.
AU - Serafim da Silveira, Leonardo
AU - Tarkowski, Andrej
AU - Torres, Jose V
PY - 2000
Y1 - 2000
N2 - Staphylococcus aureus causes many diseases including cellulitis, keratitis, osteomyelitis, septic arthritis and mastitis. The heptapeptide RIP has been shown to prevent cellulitis in mice, which was induced by S. aureus strain Smith diffuse. Here we show that RIP can also significantly reduce the overall pathology and delay the onset of disease symptoms in several other models of S. aureus infections, including: keratitis (tested in rabbits against S. aureus 8325-4), osteomyelitis (tested in rabbits against S. aureus MS), mastitis (tested in cows against S. aureus Newbould 305, AE-1, and environmental infections) and septic arthritis (tested in mice against S. aureus LS-1). These findings substantiate that RIP is not strain specific in its inhibitory activity and that RIP is an effective inhibitor of bacterial pathology at multiple body sites following diverse routes and doses of administration. These findings strongly evidence the potential value of RIP as a chemotherapeutic agent. Copyright (C) 2000 Elsevier Science Inc.
AB - Staphylococcus aureus causes many diseases including cellulitis, keratitis, osteomyelitis, septic arthritis and mastitis. The heptapeptide RIP has been shown to prevent cellulitis in mice, which was induced by S. aureus strain Smith diffuse. Here we show that RIP can also significantly reduce the overall pathology and delay the onset of disease symptoms in several other models of S. aureus infections, including: keratitis (tested in rabbits against S. aureus 8325-4), osteomyelitis (tested in rabbits against S. aureus MS), mastitis (tested in cows against S. aureus Newbould 305, AE-1, and environmental infections) and septic arthritis (tested in mice against S. aureus LS-1). These findings substantiate that RIP is not strain specific in its inhibitory activity and that RIP is an effective inhibitor of bacterial pathology at multiple body sites following diverse routes and doses of administration. These findings strongly evidence the potential value of RIP as a chemotherapeutic agent. Copyright (C) 2000 Elsevier Science Inc.
UR - http://www.scopus.com/inward/record.url?scp=0033783672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033783672&partnerID=8YFLogxK
U2 - 10.1016/S0196-9781(00)00272-2
DO - 10.1016/S0196-9781(00)00272-2
M3 - Article
C2 - 11072116
AN - SCOPUS:0033783672
VL - 21
SP - 1301
EP - 1311
JO - Peptides
JF - Peptides
SN - 0196-9781
IS - 9
ER -